1977-06-6

Usage

Uses

Used in the Food Industry:
4-METHYL-5-THIAZOLYL METHANOL is used as a flavoring agent for its ability to impart unique taste profiles to food products, enhancing the overall sensory experience for consumers.
Used in the Perfume Industry:
Leveraging its strong odor, 4-METHYL-5-THIAZOLYL METHANOL is utilized as a fragrance component in perfumery, contributing to the creation of complex and long-lasting scents in various personal care products.
Used in the Pharmaceutical Industry:
4-METHYL-5-THIAZOLYL METHANOL is employed in the synthesis of pharmaceuticals, serving as a key intermediate in the development of new drugs, thanks to its reactive chemical properties.
Used in the Pesticide Industry:
4-METHYL-5-THIAZOLYL METHANOL is also used in the synthesis of pesticides, where it plays a crucial role in creating effective and targeted pest control solutions.
Used in Antimicrobial and Antifungal Applications:
4-METHYL-5-THIAZOLYL METHANOL has been studied for its potential antimicrobial and antifungal properties, indicating its use in applications that require the inhibition of microbial growth, such as in preservatives or sanitizing agents.

InChI:InChI=1/C5H7NOS/c1-4-5(2-7)8-3-6-4/h3,7H,2H2,1H3

Upstream product

• 82294-70-0 4-methyl-1,3-thiazole-5-carbaldehyde 
• 20582-55-2 ethyl 4-methylthiazole-5-carboxylate 
• 7791-25-5 sulfuryl dichloride 
• 10150-87-5 1-acetoxybutan-3-one 
• 71-43-2 benzene 
• 16940-66-2 sodium tetrahydroborate 
• 20485-41-0 4-methylthiazole-5-carboxylic acid 
• 79-37-8 oxalyl dichloride 
• 81569-44-0 methyl 4-methyl thiazole-5-carboxylate 
• 115-08-2 thiocarboxamide 
• 590-90-9 1-Hydroxy-3-butanone 
• 64-17-5 ethanol 
• 66241-40-5 3-chloro-4-hydroxy-2-butanone 

Downstream Products

• 82294-70-0 4-methyl-1,3-thiazole-5-carbaldehyde 
• 20485-41-0 4-methylthiazole-5-carboxylic acid 
• 1288341-61-6 4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-[(4-methylthiazol-5-yl)methyl]aniline 
• 10014-52-5 4-methyl-5-thiazolylmethyl chloride 
• 193404-71-6 5-dimethylaminomethyl-4-methylthiazole 
• 181424-10-2 5-bromomethyl-4-methyl-thiazole 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel thiazole-derivatives as mitochondrial targeting inhibitors of cancer cells

Mitochondria are pivotal energy production sources for cells to maintain necessary metabolism activities. Targeting dysfunctional mitochondrial features has been a hotspot for mitochondrial-related disease researches. Investigation with cancerous mitochondrial metabolism is a continuing concern within tumor therapy. Herein, we set out to assess the anti-cancer activities of a novel family of TPP-thiazole derivatives based on our earlier research on mitochondrial targeting agents. Specifically, we designed and synthesized a series of TPP-thiazole derivatives and revealed by the MTT assay that most synthesized compounds effectively inhibited three cancer cell lines (HeLa, PC3 and MCF-7). After structure modifications, we explored the SAR relationships and identified the most promising compound R13 (IC50 of 5.52 μM) for further investigation. In the meantime, we performed ATP production assay to assess the selected compounds inhibitory effect on HeLa cells energy production. The results displayed the test compounds significantly restrained ATP production of cancer cells. Overall, we have designed and synthesized a series of compounds which exhibited significant cytotoxicity against cancer cells and effectively inhibited mitochondrial energy production.

Umpolung of protons from H2O: A metal-free chemoselective reduction of carbonyl compounds: Via B2pin2/H2O systems

H2O is routinely described as a proton donor, however, in the presence of diboron compounds, the umpolung reaction of H2O under metal-free conditions was successfully developed, which could afford hydride species, leading to a highly efficient and chemoselective reduction of CO bonds. This strategy exhibits excellent chemoselectivities toward carbonyl groups in the presence of ester, olefin, halogen, thioether, sulfonyl, cyano as well as heteroaromatic groups.

Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity

Earlier we reported the discovery and design of NBD-556 and their analogs which demonstrated their potential as HIV-1 entry inhibitors. However, progress in developing these inhibitors has been stymied by their CD4-agonist properties, an unfavorable trait for use as drug. Here, we demonstrate the successful conversion of a full CD4-agonist (NBD-556) through a partial CD4-agonist (NBD-09027), to a full CD4-antagonist (NBD-11021) by structure-based modification of the critical oxalamide midregion, previously thought to be intolerant of modification. NBD-11021 showed unprecedented neutralization breath for this class of inhibitors, with pan-neutralization against a panel of 56 Env-pseudotyped HIV-1 representing diverse subtypes of clinical isolates (IC50 as low as 270 nM). The cocrystal structure of NBD-11021 complexed to a monomeric HIV-1 gp120 core revealed its detail binding characteristics. The study is expected to provide a framework for further development of NBD series as HIV-1 entry inhibitors for clinical application against AIDS.

PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL

Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

CARBACEPHEM BETA-LACTAM ANTIBIOTICS

Carbacephem β-lactam antibiotics having structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, X, R1 and R2 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.

METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS

The present invention relates to pyrimidine derivatives of Formula (Ia) and (Ib) (including tautomers, isomers, prodrugs, and pharmaceutically acceptable salts thereof). Said compounds are useful in the treatment of pain (such as neuropathic pain), inflammation, and epilepsy (by acting as anticonvulsants). Methods of medical treatment making use of said compounds, as well as additional compounds of Formula (IIa) and (IIb), are also disclosed.

QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS

The present invention relates to novel quinolones of Formula I that inhibit inducible NOS synthase together with methods of synthesizing and using the compounds including methods for inhibiting or modulating nitric oxide synthesis and/or lowering nitric oxide levels in a patient by administering the compounds for the treatment of disease.

PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS

The invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein Ar1, Ar2, A, X, Y, m, n and R1 to R5 are described in the specification.

PREPARATION OF INTERMEDIATE FOR 3-[2-(4-METHYLTHIAZOLE-5-YL)VINYL] CEPHALOSPORINS

The present invention relates to the preparation of 4-methylthiazol-5-carboxaldehyde of Formula I, and use thereof as an intermediate in preparation of 3-[2-(4-methylthiazole-5-yl)vinyl] cephalosporins.

Process for the preparation of thiazole intermediate

The present invention provides a process for the preparation of 4-methyl-5-formyl-thiazole of the formula (I) which comprises reducing the thiazole ester of the formula (III) to thiazole alcohol of the formula (IV), using sodium borohydride in the presence of AlCl3 in a solvent and oxidising using an oxidizing agent the thiazole alcohol of the formula (IV) to obtain 4-methyl-5-formyl-thiazole of the formula (I).